Name | Bemarituzumab |
---|
Description | Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research[1]. |
---|---|
Related Catalog | |
References |
No Any Chemical & Physical Properties |